Jamil Allen Gamboa Fortaleza

Mr. Jamil Allen Gamboa Fortaleza


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2024 in European Journal of Microbiology and Immunology
Verified
Journal Article
Open access
PDF file
JFJamil Allen Gamboa Fortaleza
Jamil Allen Gamboa Fortaleza
COChristian Joseph Ong
Christian Joseph Ong
RJRener De Jesus
Rener De Jesus
Staphylococcus aureus infections have already presented a substantial public health challenge, encompassing different clinical manifestations, ranging from bacteremia to sepsis and multi-organ failures. Among these infections, methicillin-resistant S. aureus (MRSA) is particularly alarming due to its well-documented resistance to multiple classes of antibiotics, contributing significantly to global mortality rates. Consequently, the urgent need for effective treatment options has prompted a growing interest in exploring phage therapy as a potential non-antibiotic treatment against MRSA infections. Phages represent a class of highly specific bacterial viruses known for their ability to infect certain bacterial strains. This review paper explores the clinical potential of phages as a treatment for MRSA infections due to their low toxicity and auto-dosing capabilities. The paper also discusses the synergistic effect of phage-antibiotic combination (PAC) and the promising results from in vitro and animal model studies, which could lead to extensive human clinical trials. However, clinicians need to establish and adhere to standard protocols governing phage administration and implementation. Prominent clinical trials are needed to develop and advance phage therapy as a non-antibiotic therapy intervention, meeting regulatory guidelines, logistical requirements, and ethical considerations, potentially revolutionizing the treatment of MRSA infections.

16 December 2025 in European Journal of Microbiology and Immunology
Verified
Journal Article
Open access
COChristian Joseph Ong
Christian Joseph Ong
OEOluwagbemisola Elizabeth Elesho
Oluwagbemisola Elizabeth Elesho
BBBolorunduro Babatunde Bramwell
Bolorunduro Babatunde Bramwell
KCKevin Smith Puno Cabuhat
Kevin Smith Puno Cabuhat
GBGrace D. Bacalzo
Grace D. Bacalzo
JFJamil Allen Gamboa Fortaleza
Jamil Allen Gamboa Fortaleza
Staphylococcus aureus is a clinically important bacterial pathogen causing infections from superficial skin lesions to life-threatening systemic diseases. The emergence of methicillin-resistant S. aureus (MRSA) has compounded the global health burden, particularly in low- and middle-income countries, as its quorum-sensing (QS) mediated mechanisms contribute to its persistence, resistance, and evasion from host immune responses and antimicrobial treatments. Thus, these features compromise the effectiveness of conventional antibiotics, urging the need for alternative therapeutic approaches. To resolve these issues, several non-antibiotic antibiofilm approaches have been developed. Bacteriophages and phage-derived enzymes show promising specificity in lysing bacterial cells and disrupting biofilms. Antimicrobial peptides (AMPs), with their broad-spectrum activity, destabilize bacterial membranes and modulate immune responses. Monoclonal antibodies can neutralize toxins or inhibit adhesion molecules within biofilms. Phytochemicals have demonstrated activity against QS pathways and efflux pumps. Metal ion chelators like deferiprone interfere with iron acquisition, which is essential for biofilm stability. Nanoparticles (NPs), ranging from metallic and polymeric to lipid-based and cyclodextrin-based systems, enhance drug delivery and biofilm penetration. CRISPR-Cas systems provide precise genome editing to target resistance genes and virulence factors. Rhamnolipids disrupt biofilm matrix integrity, while enzymes such as dispersin B degrade extracellular polymeric substances. Photodynamic and laser therapies offer localized disruption of biofilm structures through oxidative stress. Collectively, this review offers a transformative complementary approach to traditional antibiotics, enhancing treatment efficacy while potentially reducing the emergence of resistance. Continued research on delivery systems, safety profiles, and synergistic combinations will be pivotal for their clinical translation against S. aureus infections.

12 March 2026 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
JFJamil Allen Gamboa Fortaleza
Jamil Allen Gamboa Fortaleza
KCKevin Smith P. Cabuhat
Kevin Smith P. Cabuhat
SKShukho Kim
Shukho Kim
FMFerdinand A. Mortel
Ferdinand A. Mortel
GBGrace D. Bacalzo
Grace D. Bacalzo
JNJose Jurel M. Nuevo
Jose Jurel M. Nuevo
Acinetobacter baumannii has become a prominent healthcare-associated pathogen due to its exceptional environmental persistence, biofilm-forming capacity, and the global emergence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant lineages. The declining effectiveness of conventional antibiotics has renewed interest in bacteriophage-based strategies as alternative or adjunctive antimicrobial approaches. This review provides a comprehensive synthesis of recent advances in bacteriophages targeting A. baumannii , integrating microbiological, structural, immunological, and translational perspectives that shape therapeutic efficacy and resistance dynamics. We highlight the central role of bacterial surface structures, including capsular polysaccharides, outer membrane proteins, and lipooligosaccharides, which act simultaneously as virulence determinants, phage receptors, and modulators of antimicrobial susceptibility. Phage-mediated antibacterial activity is achieved through receptor-specific lysis, biofilm disruption, capsule and envelope remodeling, and indirect resensitization to antibiotics, frequently accompanied by fitness trade-offs in phage-resistant bacterial subpopulations. We further discuss how formulation strategies, phage-derived enzymes, engineered phages, and phage–antibiotic combinations influence treatment outcomes, with particular attention to delivery routes, dosing strategies, and host immune context. Importantly, we distinguish direct phage effects from secondary immunological consequences of bacterial clearance and critically evaluate evidence from in vitro studies, animal infection models, and emerging clinical reports. Finally, we examine regulatory and manufacturing challenges that currently limit broader clinical translation. This review positions bacteriophage-based interventions as a promising, evolution-aware complement to antibiotics for managing drug-resistant A. baumannii , while underscoring the requirements for their rational and durable clinical implementation.

23 April 2026 in Waste Management Bulletin
Verified
Journal Article
Open access
JFJamil Allen Gamboa Fortaleza
Jamil Allen Gamboa Fortaleza
Michael Dare AsemoloyeMichael Dare Asemoloye
Michael Dare Asemoloye
MTMemory Tekere
Memory Tekere
ACAubrey Dickson Chigwada
Aubrey Dickson Chigwada
XZXuening Zhou
Xuening Zhou
RJRener S. De Jesus
Rener S. De Jesus

4 May 2026 in Virulence
Verified
Journal Article
Open access
JFJamil Allen Gamboa Fortaleza
Jamil Allen Gamboa Fortaleza
KCKevin Smith Puno Cabuhat
Kevin Smith Puno Cabuhat
COChristian Joseph Ong
Christian Joseph Ong
Ferdinand Apolonio MortelFerdinand Apolonio Mortel
Ferdinand Apolonio Mortel
GBGrace D. Bacalzo
Grace D. Bacalzo
JNJose Jurel M. Nuevo
Jose Jurel M. Nuevo
Acinetobacter baumannii, once regarded as a low-virulence organism, has emerged as a major global pathogen due to the rapid dissemination of multidrug-resistant (MDR), extensively drug-resistant (X...

31 December 2025 in European Journal of Microbiology and Immunology
Verified
Journal Article
Open access
KCKevin Smith Puno Cabuhat
Kevin Smith Puno Cabuhat
TTTroy Vincent C. Tan
Troy Vincent C. Tan
COChristian Joseph Ong
Christian Joseph Ong
Ferdinand Apolonio MortelFerdinand Apolonio Mortel
Ferdinand Apolonio Mortel
GBGrace D. Bacalzo
Grace D. Bacalzo
JFJamil Allen Gamboa Fortaleza
Jamil Allen Gamboa Fortaleza
Antimicrobial resistance (AMR), particularly in methicillin-resistant Staphylococcus aureus (MRSA), continues to threaten global health due to its multidrug resistance and strong biofilm-forming ability. Antimicrobial peptides (AMPs) have emerged as promising agents against MRSA biofilms because of their diverse origins, structural versatility, and unique modes of action. Natural AMPs derived from animals, plants, fungi, protists, archaea, and bacteria primarily act by disrupting bacterial membranes, interfering with quorum sensing, and downregulating biofilm-related genes such as sarA , icaA , and icaD . Synthetic AMPs, designed through computational modeling and machine learning, demonstrate enhanced stability, reduced toxicity, and improved target specificity. Synergistic AMP–antibiotic combinations, including nisin, indolicidin, and α-MSH analogs with β-lactams, significantly improve antibiofilm efficacy and bacterial clearance. Despite these advances, challenges persist due to peptide instability, enzymatic degradation, cytotoxicity, and limited in vivo validation. Recent developments in nanoparticle, hydrogel, coatings, and nanofiber delivery systems have improved AMP bioavailability and controlled release within biofilms. Continued integration of peptide engineering, nanotechnology, and bioinformatics-driven design offers promising solutions for clinical translation. Overall, AMPs represent a frontier in combating MRSA biofilms and antibiotic resistance, with future research focusing on stability enhancement, resistance prevention, and optimized therapeutic delivery.